Rozprawy doktorskie na temat „Benign prostatic hyperplasia”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych rozpraw doktorskich naukowych na temat „Benign prostatic hyperplasia”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj rozprawy doktorskie z różnych dziedzin i twórz odpowiednie bibliografie.
Jia, Guang. "MR imaging biomarkers for benign prostatic hyperplasia pharmacotherapy". Columbus, Ohio : Ohio State University, 2006. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1164686290.
Pełny tekst źródłaAmbrosini, Gina L. "Dietary risk factors for prostate cancer and benign prostatic hyperplasia". University of Western Australia. School of Population Health, 2008. http://theses.library.uwa.edu.au/adt-WU2008.0135.
Pełny tekst źródłaWoo, Henry Hyunshik. "Evolution of minimally invasive surgical treatments for benign prostatic obstruction". Thesis, The University of Sydney, 2016. http://hdl.handle.net/2123/15772.
Pełny tekst źródłaGilmore, Paul Edward. "Isolation and characterization of stem cell phenotype in benign prostatic hyperplasia and prostate cancer". Thesis, University of Manchester, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.492891.
Pełny tekst źródłaChan, Hin-cheong. "The psychometric evaluation of the Chinese version of the international prostate symptom score (IPSS)". Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/hkuto/record/B31972871.
Pełny tekst źródłaNoble, Amanda Jane. "The alphaâ†1-andrenoceptor subtype mediating contraction of the lower urinary tract". Thesis, University of Sheffield, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.284384.
Pełny tekst źródłaXu, Kexin. "Identification and evaluation of specific marker proteins associated with human benign peostate [sic] hyperplasia /". Hong Kong : University of Hong Kong, 2002. http://sunzi.lib.hku.hk/hkuto/record.jsp?B25435863.
Pełny tekst źródłaFernandes, Ancilla W. "Evaluating diagnostic and treatment modalities in the management of benign prostatic hyperplasia in the Veterans Administration population". Morgantown, W. Va. : [West Virginia University Libraries], 2000. http://etd.wvu.edu/templates/showETD.cfm?recnum=1543.
Pełny tekst źródłaTitle from document title page. Document formatted into pages; contains ix, 154 p. : ill. Includes abstract. Includes bibliographical references (p. 137-143).
Tayeb, Mohammed Taher. "Genetic risk factors influencing the development of prostate cancer in patients with benign prostatic hyperplasia". Thesis, University of Aberdeen, 2002. http://digitool.abdn.ac.uk/R?func=search-advanced-go&find_code1=WSN&request1=AAIU154536.
Pełny tekst źródłaHallin, Anders. "Transurethral microwave thermotherapy of benign prostatic hyperplasia : a clinical and methodological evaluation /". Stockholm, 1997. http://diss.kib.ki.se/1997/91-628-2727-8.
Pełny tekst źródłaHerrera, Maria Lourdes C. "The expression of various growth factors in the normal human prostate, benign prostatic hyperplasia, and prostate carcinoma". Thesis, Hong Kong : University of Hong Kong, 1996. http://sunzi.lib.hku.hk/hkuto/record.jsp?B1754628X.
Pełny tekst źródłaBrehmer, Marianne. "Transurethral microwave thermotherapy of benign prostatic hyperplasia : mechanisms of action and clinical outcome /". Stockholm, 1999. http://diss.kib.ki.se/1999/91-628-3857-1/.
Pełny tekst źródłaXu, Kexin, i 許克新. "Identification and evaluation of specific marker proteins associated with human benign peostate [sic] hyperplasia". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2002. http://hub.hku.hk/bib/B31226954.
Pełny tekst źródłaPaul, Alan Burnett. "β-NGF and its low-affinity receptor (p75LNGFR) in benign prostatic hyperplasia and adenocarcinoma of the prostate". Thesis, University of Edinburgh, 1999. http://hdl.handle.net/1842/29936.
Pełny tekst źródłaMaestri, Valentina <1984>. "Design and synthesis of multipotent drugs: application to Alzheimer's disease and benign prostatic hyperplasia". Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2013. http://amsdottorato.unibo.it/5280/1/Maestri_Valentina_tesi.pdf.
Pełny tekst źródłaMaestri, Valentina <1984>. "Design and synthesis of multipotent drugs: application to Alzheimer's disease and benign prostatic hyperplasia". Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2013. http://amsdottorato.unibo.it/5280/.
Pełny tekst źródłaAlmeida, Neto Adauto 1977. "Abordagem quantitativa da expressão do gene WFDC1 e sua isoforma delta 3 = Quantitative approach of the expression of WFDC1 gene and its isoform delta 3". [s.n.], 2014. http://repositorio.unicamp.br/jspui/handle/REPOSIP/317579.
Pełny tekst źródłaTese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia
Made available in DSpace on 2018-08-25T14:18:25Z (GMT). No. of bitstreams: 1 AlmeidaNeto_Adauto_D.pdf: 4167026 bytes, checksum: ca3afd135b583810d6996e33016f9e69 (MD5) Previous issue date: 2014
Resumo: A próstata é alvo de afecções severas que comprometem a função urinária, a qualidade de vida e que consistem em risco de vida aos indivíduos do sexo masculino, particularmente com o avançar da idade. Interações dinâmicas entre o epitélio prostático e o estroma, regulam vários aspectos do desenvolvimento, da função e das patologias prostáticas. O gene WFDC1 é expresso pelas células musculares lisas do estroma prostático normal e tem função na regulação do comportamento do epitélio, na organização da matriz extracelular e na regulação da angiogênese. Dois transcritos principais são oriundos de splicing alternativo do transcrito primário: um com todos os éxons (WFDC1) e outro sem o éxon 3 (Delta 3). Neste trabalho, investigamos as relações quantitativas entre estas duas variantes, com emprego de qRT-PCR (Taqman) e sondas para as junções dos éxons 2-3 e 2-4, em amostras de hiperplasia prostática benigna (BPH) e de câncer de próstata (PCA) provenientes de bancos de tecidos. A expressão do gene marcador MYH11 foi utilizada como estimativa do conteúdo de células musculares lisas nas amostras. Os resultados demonstraram que as amostras puderam ser dividas em dois grupos com expressão diferencial da MYH11(um com baixa expressão e outro com alta miosina, sendo o primeiro correspondente ao quartil inferior da distribuição dos valores de expressão). Foi demonstrada correlação entre a expressão de WFDC1 e MYH11 em BPH, mas não em PCA, enquanto não houve correlação entre Delta 3 e WFDC1 e nem com MYH11. O conteúdo de Delta 3 variou em cinco ordens de magnitude em comparação ao de WFDC1. A razão entre as duas variantes apresentou variação exponencial, distribuições discretas e intercaladas das amostras de BPH e de PCA, que se distribuíram em populações que preservaram as relações 10:1; 1:1 e 1:3. Poucas amostras estiveram livres de cada uma destas variantes. Em conclusão, a expressão do gene WFDC1 e de sua variante WFDC1 correlaciona-se com a diferenciação das células musculares lisas, mas não está condicionada a ela, enquanto a expressão de Delta 3 é completamente independente deste parâmetro e tem correlação positiva com o progressão do PCA, quando o sistema de classificação de Gleason (Gleason 1 + Gleason 2) foi considerado. Adicionalmente, fatores independentes da idade, incidência de BPH ou PCA, são mais influentes na determinação da quantidade total e da proporção entre as duas variantes
Abstract: The prostate gland is intimately related with reproductive and urinary functions, commonly disturbed by a series of diseases. Besides reducing the quality of life, they consist in serious life risk particularly to the aging men. Dynamic interactions between the epithelium and stroma in the gland regulate various aspects of development, function and pathologies. The WFDC1 gene is expressed by smooth muscle cells in the prostate stroma and its product ps20 was shown to control epithelial cell behavior, extracellular matrix organization and angiogenesis. It is supposed to function as a serine protease inhibitor, as other members of its family do. Two transcripts are produced as a result of alternative splicing. The first (WFDC1) retains all exons and the second (Delta 3) lacks the exon 3. In this work, we investigated the quantitative relationship among these two splicing variants, using qRT-PCR (Taqman) probing the junctions between exons 2-3 and 2-4, in benign prostatic hyperplasia (BPH) and prostate cancer (PCA) samples from tissue banks. The expression of the MYH11 gene was used to estimate the content of smooth muscle cells in the samples. The results demonstrate that the samples could be divided in two groups with low or high expression of MYH11, the first corresponding to the lower quartile of expression values). WFDC1 and MYH11 expression were correlated in the BPH samples. Delta 3 expression was independent of both WFDC1 and from WFDC1. The ratio between the variants WFDC1 and Delta 3 varied exponentially in five orders of magnitude. The the ratio between the two variants also varied exponentially, with BPH and PCA samples arranged in discrete and intercalated subgroups. The distribution of populations with different expression levels preserved the ratios 10:1, 1:1 and 1:3. Either variant was absent in only a few samples. In conclusion, the expression of WFDC1 and it WFDC1 variant correlates with but is not conditioned to the differentiation of smooth muscle cells, while Delta 3 is completely independent and is positively correlated with PCA grade (as assessed by the summed Gleason score). Unknown factors independent of age, BPH or PCA incidence are likely influencing Delta 3 expression
Doutorado
Biologia Celular
Doutor em Biologia Celular e Estrutural
Hakenberg, Oliver W., Christian Helke, Andreas Manseck i Manfred P. Wirth. "Is There a Relationship between the Amount of Tissue Removed at Transurethral Resection of the Prostate and Clinical Improvement in Benign Prostatic Hyperplasia". Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-134714.
Pełny tekst źródłaDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
Dilmen, Cem Perk Hakkı. "Prostat kanserli hastalarda leptin düzeylerinin araştırılması /". Isparta: SDÜ Tıp Fakültesi, 2004. http://tez.sdu.edu.tr/Tezler/TT00200.pdf.
Pełny tekst źródłaChan, Hin-cheong, i 陳顯昌. "The psychometric evaluation of the Chinese version of the international prostate symptom score (IPSS)". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B31972871.
Pełny tekst źródłaFröhner, Michael, Oliver W. Hakenberg, Rainer Koch, Uta Schmidt, Axel Meye i Manfred P. Wirth. "Comparison of the Clinical Value of Complexed PSA and Total PSA in the Discrimination between Benign Prostatic Hyperplasia and Prostate Cancer". Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133807.
Pełny tekst źródłaDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
Hatfield, Meghan. "PROSTASIN IS EXPRESSED IN BENIGN PROSTATIC HYPERPLASIA AND REGULATES CELL PROLIFERATION AND INVASION VIA INOS, ICAM-1, AND CYCLI". Master's thesis, University of Central Florida, 2008. http://digital.library.ucf.edu/cdm/ref/collection/ETD/id/4260.
Pełny tekst źródłaM.S.
Department of Molecular Biology and Microbiology
Burnett College of Biomedical Sciences
Molecular and Microbiology MS
VASCONCELOS, Juliana Lúcia de Albuquerque. "Avaliação do valor diagnóstico e prognóstico do carboidrato L-fucose e das fucosiltransferases 3 e 6 em tumores prostáticos humano". Universidade Federal de Pernambuco, 2012. https://repositorio.ufpe.br/handle/123456789/18485.
Pełny tekst źródłaMade available in DSpace on 2017-04-04T19:33:58Z (GMT). No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) 2012-Dissertação-JulianaVasconcelos.pdf: 1176748 bytes, checksum: bb96bcabc13f8fef386568e90cfdc033 (MD5) Previous issue date: 2012
Câncer é um conjunto de alterações celulares, que leva a uma divisão celular sem controle, podendo invadir tecidos adjacentes através da circulação sanguínea e do sistema linfático. O Câncer de Próstata (CP) é o segundo tumor mais comum entre a população masculina, e é considerado o câncer da terceira idade. A carcinogênese é um mecanismo complexo no qual ocorre mudanças na expressão de proteínas e glicoconjugados. Glicosilação é mediada por glicosiltransferases, enzimas que tem função de inserir resíduos de carboidratos específicos, e é um dos mais importantes processos biológicos pós-tradução de modificações na estrutura final e função de lipídios e proteínas. As fucosiltransferases (FUT) participam da transferência de resíduos de L-fucose, um sacarídeo associado ao câncer e a processos inflamatórios, da GDP-L-fucose. Neste estudo objetivou-se avaliar a expressão dos genes FUT3 e FUT6 através da Imunohistoquímica em Adenocarcinoma Prostático e Hiperplasia Prostática Benigna correlacionando com o padrão de expressão de L-fucose empregando a histoquímica com as lectinas UEA-I (Ulex europaeus) e LTA (Lotus tetragonolobus). As enzimas FUT3 e FUT6 apresentaram-se com uma alta expressão tanto no Adenocarcinoma Prostático como na Hiperplasia Benigna Prostática, principalmente a FUT 6. Os resultados da histoquímica com lectinas mostraram uma baixa distribuição/accessibilidade de L-fucose. Sugere-se que, as enzimas FUT3 e FUT6 possam representar potenciais biomarcadores para avaliar alterações benignas e malignas prostáticas refletindo uma variação no perfil de L-fucose nestes tumores que podem estar associados às suas características biológicas.
Cancer is a set of cellular changes, leading to uncontrolled cell division that may invade surrounding tissues via bloodstream and lymphatic system. Prostate Cancer (PC) is the second most common tumor in men and is considered the cancer of the elderly. Carcinogenesis is a complex mechanism in which changes occur in the expression of proteins and glycoconjugates where glycosylation plays key roles since modulates the carbohydrate moieties in glycoconjugates being one of the most important biological processes of posttranslational modifications in the final structure and function of lipids and proteins. Fucosyltransferases (FUTs) are enzymes that catalyze the transfer of the L-fucose residues, a saccharide which has been linked to cancer and inflammation features, from GDP-Fuc. This study the objective to evaluate the expression of genes FUT 3 and FUT 6 by immunohistochemistry in Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia and to correlates with the expression pattern of L-fucose using lectin histochemistry with UEA-I (Ulex europaeus) and LTA (Lotus tetragonolobus). FUT3 and FUT6 showed a high expression in both prostatic tissues, especially FUT6. The results of lectin histochemistry showed a low distribution/accessibility of L-fucose residues. It is suggested that FUT3 and FUT6 may represent potential biomarkers to evaluate benign and malignant alterations in prostate reflecting a variation in the profile of L-fucose residues in these tumors which can be associated to their biological features.
Hakenberg, Oliver W., Christian Helke, Andreas Manseck i Manfred P. Wirth. "Is There a Relationship between the Amount of Tissue Removed at Transurethral Resection of the Prostate and Clinical Improvement in Benign Prostatic Hyperplasia". Karger, 2001. https://tud.qucosa.de/id/qucosa%3A26541.
Pełny tekst źródłaDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
Sahlén, Göran. "Formation, storage and secretion of prostasomes in benign and malignant cells and their immunogenicity in prostate cancer patients /". Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-7511.
Pełny tekst źródłaFröhner, Michael, Oliver W. Hakenberg, Rainer Koch, Uta Schmidt, Axel Meye i Manfred P. Wirth. "Comparison of the Clinical Value of Complexed PSA and Total PSA in the Discrimination between Benign Prostatic Hyperplasia and Prostate Cancer". Karger, 2006. https://tud.qucosa.de/id/qucosa%3A27537.
Pełny tekst źródłaDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
Kelly-Blake, Karen Denise. "Sexual (dys)function and benign prostate disease implications for health care decision-making /". Diss., Connect to online resource - MSU authorized users, 2008.
Znajdź pełny tekst źródłaMIYAKE, KOJI, HATSUKI HIBI i MASANORI YAMAMOTO. "A COMPARISON OF TRANSURETHRAL RESECTION OF THE PROSTATE AND MEDICAL TREATMENT FOR THE PATIENT WITH MODERATE SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA". Nagoya University School of Medicine, 1996. http://hdl.handle.net/2237/16096.
Pełny tekst źródłaMonjardez, Geraldine. "The feasibility of Fourier transform infrared imaging spectroscopy in discriminating benign prostatic hyperplasia from prostate cancer in blood serum samples". Thesis, University of Manchester, 2013. https://www.research.manchester.ac.uk/portal/en/theses/the-feasibility-of-fourier-transform-infrared-imaging-spectroscopy-in-discriminating-benign-prostatic-hyperplasia-from-prostate-cancer-in-blood-serum-samples(b0fbd4e3-4a23-4696-a480-c83be32a671c).html.
Pełny tekst źródłaUpreti, Rita. "Metabolic effects of 5α-reductase inhibition in humans". Thesis, University of Edinburgh, 2013. http://hdl.handle.net/1842/11745.
Pełny tekst źródłaKim, Julie M. "Androgen-induced norepinephrine release in male accessory sex organ smooth muscle growth and differentiation". Morgantown, WV : [West Virginia University Libraries], 1999. http://etd.wvu.edu/templates/showETD.cfm?recnum=417.
Pełny tekst źródłaTitle from document title page. Document formatted into pages; contains vi, 125 p. : ill. Vita. Includes abstract. Includes bibliographical references (p. 107-122).
Robert, Grégoire. "Rôle de l'inflammation prostatique chronique dans le développement de l'hyperplasie bénigne de la prostate". Thesis, Paris Est, 2011. http://www.theses.fr/2011PEST0099.
Pełny tekst źródłaGunnarsson, Jenny, i Madeleine Lundin. "Benign Prostatahyperplasi. Upplevelser och livskvalitet hos män med benign prostatahyperplasi". Thesis, Malmö högskola, Fakulteten för hälsa och samhälle (HS), 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:mau:diva-24279.
Pełny tekst źródłaBenign prostatic hyperplasia (BPH) is a condition which causes urology bother that might have an impact on quality of life and daily living in almost all men over the age 80. The aim of this study was to report on how men with benign prostatic hyperplasia experiencing their daily lives and how their quality of life is affected. A systematic review was made in accordance to a systematic procedure. The literature searching was made in the databases CINAHL, PsycInfo, PubMed and The Cochrane Library. Both quantitative and qualitative studies were included and the quality was assessed by both authors independently of each other using a modified audit protocol. The results show that men with BPH have disturbed sleep due to nocturia, limiting their social lives and experiencing embarrassment over the urological symptoms and a negative impact on the sexual life. Men with BPH also seems to develop coping strategies to overcome their daily lives such as reducing fluid intake, talk about the complaint and accept the condition. It also seems that it is more common for men with BPH to rank their quality of life lower than men without BPH. More studies using both qualitative and quantitative approach are needed to find a deeper understanding of men with BPH and to strengthen evidences about quality of life and daily life.
Ju, Mingxuan. "Machine Learning for Responsiveness of Medication in Bladder and Prostate Syndromes". Case Western Reserve University School of Graduate Studies / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=case1586449819233263.
Pełny tekst źródłaStåhl, Joanna, i Moa Ericzon. "Att leva med icke-malign prostataförändring : en litteraturöversikt". Thesis, Sophiahemmet Högskola, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:shh:diva-3529.
Pełny tekst źródłaBackground Non-malignant prostatic conditions are a prevalent problem in society and a common reason as to why people seek medical care. Prostatitis and benign prostatic hyperplasia are two examples of non-malignant conditions that can appear in different ways and that could cause the afflicted person suffering, oftentimes through symptoms like pain and lower urinary tract symptoms. Alleviating suffering is an undertaking of health-care professionals’ and a nurse’s responsibility. Aim The aim of this literature review was to illuminate what it is like to live with a non-malignant prostatic condition. Method Non-systematic literature review where 18 articles were analyzed. Results The results of the included and analyzed studies show that non-malignant prostatic conditions can influence intimate relationships, cause feelings of shame, fear and worry, that there are factors that can be more or less favourable in relation to these conditions and that there is room for improvement in the meeting with healthcare professionals. Conclusions The results in this non-systematic literature review show that living with non-malignant prostatic conditions, and the symptoms they cause, can have a significant influence on the affected persons’ lives and quality of life in several aspects.
Zambra, Francis Maria Báo. "Influência dos genes CCR2 e CCR5 em hiperplasia e câncer de próstata". reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2012. http://hdl.handle.net/10183/69706.
Pełny tekst źródłaBenign prostatic hyperplasia (BPH) and prostate cancer (PCa) are two chronic conditions very common in aged men and have been related to inflammatory process. Chemokines are recognized as critical mediators of inflammatory responses by regulating the migration of immune cells through the activation of chemokine receptors on the surface of these cells. Chemokines are implicated in tumor pathogenesis, although it is not clear how it affects human tumor progression. The aim of this study was to investigate the association of two chemokine receptor gene polymorphisms, CCR2-64I and CCR5-delta32, with BPH and PCa. In this study were genotyped 385 genomic DNA samples from southernmost Brazilian men, predominantly euro-descendants, including 130 BPH, 136 PCa and 119 healthy control subjects. To CCR2-64I polymorphism the genotyping was performed by PCR-RFLP and to CCR5-delta32 by conventional PCR. The allele frequencies of CCR2-64I were 14.0%, 15.8% and 11.1% in control, BPH and PCa, respectively; while of CCR5-delta32 were 5.1%, 7.1% and 6.2%, respectively. Median of serum PSA levels were 0.79, 1.45 and 6.91 ng/mL in control, BPH and PCa group, respectively (all p<0.001). The prostate volume median was 20.00 cm3 in the control group, thus, lower than BPH (35.35 cm3) and PCa (35.80 cm3) group (both p<0.001), nevertheless no difference was observed between BPH and PCa patients (p=0.172). Interestingly, CCR2-64I was detected as a protective factor to PCa when compared with BPH (OR=0.550; 95%CI=0.311–0.975), but not when compared with control group (p=0.448). No significant associations of the CCR2-64I were observed with PCa clinicopathologic states (tumor stage and Gleason score) (all p≥0.308). No significant associations of the CCR5-delta32 variant were observed with BPH or PCa (all p≥0.072), or with PCa clinicopathologic status (all p≥0.253). Thus, our data suggest a influence of the CCR2-64I variant, that was observed as a protective factor in PCa when compared with BPH, in prostate cancer development.
Mostachio, Giuliano Queiroz [UNESP]. "Estudo comparativo entre a administração de toxina botulínica “A” e a orquiectomia no tratamento da hiperplasia prostática benigna do cão". Universidade Estadual Paulista (UNESP), 2008. http://hdl.handle.net/11449/89061.
Pełny tekst źródłaFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
A hiperplasia prostática benigna (HPB) tem início no animal com um a dois anos de idade, sendo que 80% dos cães com cinco anos apresentam evidências histológicas de sua presença. A fisiopatologia da doença não está totalmente compreendida, no entanto, a diidrotestosterona é o principal hormônio envolvido. Recentemente, o efeito da toxina botulínica A (TB-A) foi investigado na próstata, mostrando que esta induz atrofia do parênquima e redução do volume. Como o cão é o único animal doméstico que apresenta esta alteração, este se apresenta como modelo experimental para novos estudos da HPB humana. Com base nisso, este estudo objetivou fornecer informações acerca dos efeitos da TB-A sobre a próstata, libido e qualidade do sêmen, comparando os dados com animais orquiectomizados. Para tanto, 18 cães adultos, com evidências ultra-sonográficas de HPB foram submetidos à castração ou administração de 250 ou 500 U de TB-A, e avaliados durante 16 semanas. A orquiectomia mostrou-se um excelente tratamento para a HPB, promovendo redução de 80% do volume prostático. Aplicação da TB-A não ocasionou alterações significativas na libido, ereção ou qualidade e características seminais. Efeitos locais e sistêmicos também não foram observados. Administração de 250 U da TB-A promoveu redução máxima de 9,4% do volume prostático, entretanto, tal redução não foi significativa. Por outro lado, a administração de 500 U de TB-A reduziu significamente as variáveis comprimento, altura e volume da próstata. Desta forma, o presente ensaio contribui de forma singular e inovadora para o conhecimento dos efeitos desta nova modalidade de tratamento na HPB canina.
Benign prostatic hyperplasia (BPH) starts the development in animals aging about 1 – 2 years. 80% of 5 years-old dogs have histologic evidences of BPH. Despite the little knowledge concerning about this disease, dihydrotestosterone is the main involved hormone. Recently, the effect of botulinum toxin A (BT-A) on rat and human prostate was investigated, and prostatic parenchyma atrophy and decrease in glandular volume were observed. The dog is one of a few animals that can develop BPH spontaneously and is frequently used as an animal model for human prostatic hyperplasia. Based on that, this study aimed to provide information on BT-A effects on prostate, libido and semen quality, in comparison to orchiectomized dogs. For that, 18 adults dogs, with Ultrasonographic evidences of BPH were submitted to orchiectomy or administration of 250 or 500 U of BT-A, and evaluated along 16 weeks. Orchiectomy presented excellent results on BPH, reducing the prostate volume up to 80%. Administration of BT-A did not significantly interfered on libido, erection or semen characteristics. Local and systemic effects also were not observed. Administration of 250 U of BT-A has promoved a maximum decrease of 9,4% on prostatic volume. However, this reduction was not statistically significant. On the other hand, 500 U of BTA administration has shown to significantly reduce the length, height and volume of prostate. This way, the present study is an innovative and singular contribution for the knowledge of the effects of BT-A on canine prostate.
Manaia, Jorge Henrique Martins. "Estudo qualitativo e quantitativo dos componentes fibrosos da matriz extracelular e músculo liso da uretra prostática de pacientes com hiperplasia prostática benigna, da zona de transição, de pacientes com hiperplasia prostática benigna". Niterói, 2016. https://app.uff.br/riuff/handle/1/4584.
Pełny tekst źródłaApproved for entry into archive by Ana Lúcia Torres (bfmhuap@gmail.com) on 2017-09-20T15:55:06Z (GMT) No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) JORGE HENRIQUETESE COM CORREÇÕES DA BANCA JAN 2017.pdf: 4201838 bytes, checksum: f47ae0fb55a2d648c74ac2facf85217d (MD5)
Made available in DSpace on 2017-09-20T15:55:06Z (GMT). No. of bitstreams: 2 license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) JORGE HENRIQUETESE COM CORREÇÕES DA BANCA JAN 2017.pdf: 4201838 bytes, checksum: f47ae0fb55a2d648c74ac2facf85217d (MD5) Previous issue date: 2016
Universidade Federal Fluminense. Centro de Ciências Médicas. Instituto Biomédico. Departamento de Morfologia. Anatomia Humana
A uretra masculina humana possui uma macro estrutura uniforme. Apesar disso apresenta evidências clínicas, morfológicas e moleculares ao longo de seus segmentos, que indicam haver diferenças estruturais e patológicas entre os mesmos. A maioria das alterações da uretra prostática (UP), em homens acima dos 50 anos, são consideradas como sendo secundárias à compressão devido ao crescimento de nódulos fibromatosos hiperplásicos do tecido prostático. Os sinais obstrutivos consequentes a Hiperplasia Prostática Benigna (HPB) incluem hesitação para iniciar a micção, redução da força e calibre do jato urinário, bem como, tardiamente, retenção urinária. Para tentar explicar as alterações que ocorreram na estrutura histológica da UP, no processo da HPB, estudamos as variações qualitativas e quantitativas que ocorreram na densidade volumétrica (Vv) do componente fibroso da matriz extracelular (MEC) e do músculo liso da UP de pacientes com HPB submetidos a tratamento cirúrgico. Foram estudadas amostras obtidas da UP de 10 pacientes com HPB sintomática, submetidos à prostatectomia aberta. Os pacientes não tinham história de tratamento prévio, para HPB. A idade dos pacientes selecionados para o presente estudo variou entre 63 a 79 anos. Para fins de comparação, foram usadas amostras controle obtidas durante a necropsia de 10 indivíduos adultos jovens com idades variando de 18 a 25 anos, vítimas de morte violenta sem comprometimento do sistema urogenital e/ou manipulação uretral. Todas as Próstatas do grupo controle apresentavam peso entre 20-25g, sendo consideradas adultas e dentro dos limites da normalidade. As amostras foram fixadas em solução de formol 10% e processadas para inclusão em parafina. Para análise da Vv, foram usadas as técnicas de coloração de tricrômico de Masson e, de Weigert. Também foram submetidas a análise imunohistoquímica. A Vv do componente fibroso da MEC e do músculo liso foi determinada pela análise de 25 campos aleatórios de cada fragmento de UP usando um sistema teste M-42. Os dados quantitativos foram analisados por meio do teste de Kolmogorov-Smirnov e Mann-Whitney. A Vv (%médio±SD) nos grupos controle e HPB foram respectivamente: 20,3±0,3 e 17,12±1,1 para as fibras do sistema elástico (p <0,007); 29,7 ± 1,9 e 25,1 ± 2,4 para colágeno (p <0,03). A Vv do músculo liso apresentou aumento, não significativo, no grupo HPB, 49,9 ± 0,4 e 52,3 ± 2,3. Por outro lado, 21,9±1,5 e 29,1±1,2 para a fibronectina (P < 0. 0001).
The human male urethra has a uniform structure. Despite this, presents morphological, molecular and clinical evidence throughout their segments that indicates pathological and structural differences between them. Most of changes in prostatic urethra (PU) in men over 50 years, are considered to be secondary to compression due to the growth of fibrous hyperplastic prostate tissue nodules. The signs of obstructive Benign Prostatic Hyperplasia (BPH) reflect the decreased distendibility of the prostatic urethra; that includes hesitation to begin urination, reduced force and caliber of the urinary stream, as well as (late) retention. To explain the histological, structural changes that occurred in the prostatic urethra, studies were made to analyse the changes in quality and quantity that occurred in the volumetric density of the fibrous component of the extracellular matrix (ECM) and smooth muscle of the urethra of patients with BPH submitted to surgical treatment. Samples were obtained from the urethra of 10 patients with symptomatic BPH who had undergone open prostatectomy. No patient had a history of previous treatment for BPH. The age ranged from 63-79 years. To compare we used control samples obtained during autopsy of 10 young adults subjects aged 18-25 that died from violent death without involvement of the urogenital system or uretral manipulation. The samples were fixed in formalin 10% and processed for paraffin embedding. For analysis of Vv, were used staining techniques tricomic Masson and Weigert. Were also submitted to immunohistochemical analysis. The Vv fibrous component of MEC and smooth muscle was determined by the analysis of 25 random fields of each fragment of a test system using M-42. Quantitative data were analyzed using the olmogorov-Smirnov and Mann-Whitney test. The Vv (mean ± SD) in the control and BPH groups respectively were: 20.3±0.3 and 17.12±1.1 in the elastic fiber system (p<0.007); and 29.7±1.9 and 25.1±2.4 in the collagen compartment (p<0.03). Smooth muscle cell volume was increased in BPH cases, 49.9±0.4 and 52.3±2.3 (not statistically significant). On other hand was 21.9±1.5 and 29.1±1.2 in the fibronectin (P < 0. 0001).
Mostachio, Giuliano Queiroz. "Estudo comparativo entre a administração de toxina botulínica "A" e a orquiectomia no tratamento da hiperplasia prostática benigna do cão /". Jaboticabal : [s.n.], 2008. http://hdl.handle.net/11449/89061.
Pełny tekst źródłaBanca: Maria Denise Lopes
Banca: Maria Isabel de Mello Martins
Resumo: A hiperplasia prostática benigna (HPB) tem início no animal com um a dois anos de idade, sendo que 80% dos cães com cinco anos apresentam evidências histológicas de sua presença. A fisiopatologia da doença não está totalmente compreendida, no entanto, a diidrotestosterona é o principal hormônio envolvido. Recentemente, o efeito da toxina botulínica A (TB-A) foi investigado na próstata, mostrando que esta induz atrofia do parênquima e redução do volume. Como o cão é o único animal doméstico que apresenta esta alteração, este se apresenta como modelo experimental para novos estudos da HPB humana. Com base nisso, este estudo objetivou fornecer informações acerca dos efeitos da TB-A sobre a próstata, libido e qualidade do sêmen, comparando os dados com animais orquiectomizados. Para tanto, 18 cães adultos, com evidências ultra-sonográficas de HPB foram submetidos à castração ou administração de 250 ou 500 U de TB-A, e avaliados durante 16 semanas. A orquiectomia mostrou-se um excelente tratamento para a HPB, promovendo redução de 80% do volume prostático. Aplicação da TB-A não ocasionou alterações significativas na libido, ereção ou qualidade e características seminais. Efeitos locais e sistêmicos também não foram observados. Administração de 250 U da TB-A promoveu redução máxima de 9,4% do volume prostático, entretanto, tal redução não foi significativa. Por outro lado, a administração de 500 U de TB-A reduziu significamente as variáveis comprimento, altura e volume da próstata. Desta forma, o presente ensaio contribui de forma singular e inovadora para o conhecimento dos efeitos desta nova modalidade de tratamento na HPB canina.
Abstract: Benign prostatic hyperplasia (BPH) starts the development in animals aging about 1 - 2 years. 80% of 5 years-old dogs have histologic evidences of BPH. Despite the little knowledge concerning about this disease, dihydrotestosterone is the main involved hormone. Recently, the effect of botulinum toxin A (BT-A) on rat and human prostate was investigated, and prostatic parenchyma atrophy and decrease in glandular volume were observed. The dog is one of a few animals that can develop BPH spontaneously and is frequently used as an animal model for human prostatic hyperplasia. Based on that, this study aimed to provide information on BT-A effects on prostate, libido and semen quality, in comparison to orchiectomized dogs. For that, 18 adults dogs, with Ultrasonographic evidences of BPH were submitted to orchiectomy or administration of 250 or 500 U of BT-A, and evaluated along 16 weeks. Orchiectomy presented excellent results on BPH, reducing the prostate volume up to 80%. Administration of BT-A did not significantly interfered on libido, erection or semen characteristics. Local and systemic effects also were not observed. Administration of 250 U of BT-A has promoved a maximum decrease of 9,4% on prostatic volume. However, this reduction was not statistically significant. On the other hand, 500 U of BTA administration has shown to significantly reduce the length, height and volume of prostate. This way, the present study is an innovative and singular contribution for the knowledge of the effects of BT-A on canine prostate.
Mestre
Opoku-Acheampong, Alexander Boadu. "Effect of 5[alpha]-reductase inhibitors on LNCaP cells, Syrian hamster flank organs, and TRAMP mice prostate cancer". Diss., Kansas State University, 2015. http://hdl.handle.net/2097/20352.
Pełny tekst źródłaDepartment of Human Nutrition
Brian L. Lindshield
The growth-inhibitory effect of saw palmetto supplements (SPS) with high long-chain fatty acids (FA)-low phytosterols (HLLP), high long-chain FA-high phytosterols (HLHP), and high medium-chain FA-low phytosterols (HMLP) was determined using androgen-sensitive LNCaP prostate cancer (PCa) cells and Syrian hamster flank organs. In vitro, all three SPS at high concentrations significantly decreased dihydrotestosterone-stimulated LNCaP cell number. HMLP and HLLP at high concentrations significantly decreased, but HLHP which significantly increased testosterone-stimulated LNCaP cell number. In Syrian hamsters, all three SPS treatments caused notable, but nonsignificant reduction in the difference between the left and right flank organ growth in the testosterone-, but not dihydrotestosterone-treated SPS groups. Results suggest SPS might be a mild 5-alpha-reductase (5-alpha-R) inhibitor. The pharmaceuticals finasteride inhibits 5-alpha-R2, and dutasteride inhibits 5-alpha-R1 and 5-alpha-R2 isoenzymes. Because finasteride inhibits only 5-alpha-R2, we hypothesized that it would not be as efficacious in preventing PCa development and/or progression in TRAMP mice as dutasteride. Six-week-old C57BL/6 TRAMP x FVB male mice were randomized to control, pre- and post- finasteride and dutasteride diet groups that began at 6 and 12 weeks of age, respectively, and terminated at 20 weeks of age. Pre and post groups received drugs before and after mice were expected to develop PCa, respectively. Post-Dutasteride treatment was significantly more effective than Pre-Dutasteride; and dutasteride treatments significantly more effective than finasteride treatments in decreasing prostatic intraepithelial neoplasia progression and PCa development. The finasteride groups and the Pre-Dutasteride group had significantly increased incidence of poorly differentiated PCa versus control. Androgen receptor and Ki-67 protein, DNA fragmentation from apoptosis, 5-alpha-R1 and 5-alpha-R2 mRNA levels were determined in mice with genitourinary weight less than 1 gram and greater than 1 gram to elucidate the discordant response in Pre-Dutasteride and finasteride groups, and Post-Dutasteride’s efficacy. Results suggest the difference in genitourinary weights is influenced more by proliferation, rather than androgen receptor and apoptosis in tumor. Mice age may not be significantly important in regulating proliferation, androgen receptor and apoptosis to promote tumor growth. In conclusion, the results with 5-alpha-reductase inhibitors may support the therapeutic use of dutasteride, but not finasteride, or saw palmetto supplements.
Trumbeckas, Darius. "Klinikinių ir urodinaminių požymių svarba prognozuojant gerybinės prostatos hiperplazijos chirurginio gydymo rezultatus". Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2006. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2006~D_20060126_155100-72148.
Pełny tekst źródłaPinedo, Pichilingue Aranza, Martín-San Martín Gustavo San i Nilton Yhuri Carreazo. "Discriminación entre hiperplasia prostática benigna y cáncer de próstata mediante el uso de PSA index en consulta externa de urología". Elsevier B.V, 2016. http://hdl.handle.net/10757/607465.
Pełny tekst źródłaObjetivo El antígeno prostático específico es utilizado en el diagnóstico de patologías prostáticas. No existe un estudio en Perú que proponga un punto de corte de PSA index para discriminar entre cáncer de próstata e hiperplasia prostática benigna para la indicación de biopsia prostática. Actualmente, se emplean diferentes puntos de corte basados en estudios internacionales. Material y métodos Se realizó un estudio de validación diagnóstica de PSA index para discriminar entre ambas entidades en pacientes con un PSA total entre 4,0 ng/ml y 9,9 ng/ml. Fueron incluidos 356 pacientes con diagnóstico de hiperplasia prostática benigna o cáncer de próstata mediante biopsia prostática. Se evaluó la sensibilidad, especificidad, los valores predictivos y los cocientes de probabilidad de los valores de PSA index de 15 hasta 25%. Se graficó la curva ROC. Resultados Un PSA index de 17% posee mejores valores de sensibilidad (87,8%), especificidad (62,2%) y valores predictivos (valor predictivo positivo de 62,4% y valor predictivo negativo de 87,4%) respecto a otros para disminuir el número de biopsias negativas. El cociente de probabilidad positivo fue 2,3 y el cociente de probabilidad negativo fue 0,1. El área bajo la curva fue 0,75 [IC 95%, 0,71 a 0,79]. Conclusión Se sugiere un PSA index de 17% como punto de corte para discriminar entre hiperplasia prostática benigna y cáncer de próstata en pacientes que acuden a consulta ambulatoria con un PSA total entre 4,0 ng/ml y 9,9 ng/ml. Se recomienda este valor si se desea reducir el número de biopsias prostáticas negativas.
Revisión por pares
Santos, Jacqueline Schaurich dos. "Padrão alimentar, perfil antropométrico e lipídico em uma amostra de indivíduos com e sem câncer de próstata ou hiperplasia prostática benigna". reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2007. http://hdl.handle.net/10183/10738.
Pełny tekst źródłaProstatic pathologies such as Benign Prostatic Hyperplasia (BPH) and Prostate Cancer (PCa) present high incidence, morbidity and mortality among individuals at the age of 40-50 years. Environmental and nutritional factors seem to be involved in the development of these diseases. The objective of the present study is to assess the alimentary pattern, anthropometric and lipid profiles in men with and without BPH and PCa and to verify whether there exists an association among the considered variables and the presence of BPH or PCa in the studied individuals. Urology outpatients from Hospital de Clínicas de Porto Alegre were interviewed by a physician who collected personal and demographic data, medical and familiar history, age, stage and degree of tumor, prostate volume and PSA value at diagnosis. Patients were directed to a nutritionist for nutritional evaluation (weight, height, skin folds, waist/hip ratio and 24-hours recall). Alimentary intake was assessed by 24-hours recall and analyzed by the nutrition support program of Escola Paulista de Medicina – EPM (DIS-EPM, version 1.5, 2002, UNIFESP). Patients were asked to return to the clinical analysis laboratory at the same hospital the following week, in order to collect another blood sample to dose serum total testosterone, total cholesterol, HDL cholesterol and triglycerides. Body Mass Index and waist circumference did not show statistical difference among the assessed groups. The BPH group presented with lower intake (p<0.05) of calories and carbohydrate (1875 ± 635 Kcal/day and 253 ± 105 g/day) when compared tothe PCa group (2017 ± 476 and 283 ± 75) and the control group (2179 ± 565 and 302 ± 91). Fiber intake (g/day) was significantly lower (p=0.01) on BPH (27 ± 12) and PCa groups (28 ± 10) when compared to control group (34 ± 15). Higher intake of fibers seems to be related to lower BPH and PCa incidence. Calories and other nutrients intake, anthropometric profile and lipid profile did not show relation to these diseases.
Araújo, Liana Maria Tôrres de. "Anestesia para ressecção transuretral de próstata: comparação entre dois períodos no HC-FMRP-USP". Universidade de São Paulo, 2004. http://www.teses.usp.br/teses/disponiveis/17/17142/tde-06042009-122239/.
Pełny tekst źródłaBenign Prostatic Hyperplasia (BPH) is the most common disease in the third ages. Transurethral Resection of the Prostate (TRP) is the surgery technique most frequently used for the treatment of BPH. Anaesthesia for this procedure has its own features becoming a challenge for the anaesthesiologist to manage with its peculiarities. In order to evaluate the anaesthetic behavior, to compare the techniques used, drugs and doses, possible complications and their treatments, three hundreds of medical records of patients submitted to TRP in the University Hospital, Faculty of Medicine of Ribeirão Preto (FM-USP). Two periods of four years were chosen (1989-1992 (period 1) and 1999-2002 (period 2)) in order to establish some evolution between the anaesthetics techniques used and possible reduction in the incidence of complications. Only patients who had benign prostatic hyperplasia were included in this study. Some patients characteristics were similar between the two groups (mean ages and physical status ASA). Mean weight were higher in the period 2. Less preoperative exams were applied in the period 1. In both periods, the regional anaesthesia was predominant (the spinal anaesthesia was the most used). Hyperbaric bupivacaine was the most commonly used agent for regional anaesthesia in both periods. More failed blocks were seen in the period 1 with an increased number of conversion to general anaesthesia. This fact may be attached with the lack of use of opioids agents in that period, which are known to complement and improve the quality of the block. Mean duration of the procedure were higher in period 2 (taking 45 minutes as standard time). The incidence of intra-operative adverse events like hypotension, cardiac arrhythmias and hypothermia were similar in both periods. However more patients had acute heart infarct in the 24 hours of postoperative period 1. Probably this happens because of the lack of preoperative exams and cardiology evaluation in patients submitted to surgery in this period. The proportion of blood transfusions were similar in two periods although it was usual to make an autotransfusion in the patients of the first period. Autotransfusion previous to the surgery were not an effective method to reduce the number of transfusions. In postanaesthesia care unit the length of stay was similar between the periods but the incidence of adverse events was higher in the period 1. The mortality was bigger in the period 2 but this difference were not significant. Key-words: 1. Anaesthesia 2. Benign Prostatic Hyperplasia 3. Transurethral Resection of the Prostate 4. The TURP Syndrome
Miranda, Mariza Abreu. "Solanum cernuum Vell: estudo fitoquímico, avaliação das atividades gastroprotetora, antimicrobiana, citotóxica e obtenção do extrato seco por spray dryer". Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/60/60138/tde-25092015-151741/.
Pełny tekst źródłaSolanum cernuum Vell. (Solanaceae), popularly known as \"panacéia\", is a native tree from Southern and Southeastern Brazil. Its traditional name is due to the wide range of uses in folk medicine including the treatment of ulcers, liver damage, skin infections, as diuretic, antitumor, depurative, anti-hemorrhagic, as well as to treat gonorrhoea and benign prostatic hyperplasia (BPH). Considering the importance of S. cernuum in folk medicine and the lack of research supporting its use, the aims of this project were to obtain different extracts, fractions and isolated compounds this plant to be tested for gastroprotective, cytotoxicity and antimicrobial activities. Leaves S. cernuum were collected in Teresópolis/RJ. The hydroethanolic (ESC) and ethyl acetate extracts were obtained from the dried and grinded leaves. Fractions in hexane (FHex), dichloromethane (FDCM), ethyl acetate (FAcOEt), n-butanol (FBuOH) and water (FAQ) were obtained from the ESC extract. The ESC extract was fractionated using different chromatographic techniques furnishing four isolated compounds: trans-isoferulic acid, cernumidine, quercitrin and afzelin. The content of these four compounds were quantified to be 1.5%, 4.8%, 1.3% and 1.6%, respectively, in the extract. ?-sitosterol and the friedelin were isolated by partitioning the ethyl acetate extract with heptane. In the antimicrobial assay, only FHex, FDCM and FAq fractions showed activity at different concentrations against the tested strains of bacteria and fungi. The hydrodistillation of the leaves of S. cernuum did not fusrnish essential oils, but the partition of the hydrolate with dichloromethane allowed the determination of its composition by GC/MS. The trichomes of S. cernuum are majority kind of stellate tector. Only FDCM fraction and friedelin compound showed activity in XTT assay against MCF-7 cells (breast carcinoma) at the concentration of 16.6 ?g/mL and 124.9 ?g/mL, respectively. The ESC extract showed gastroprotective effects in the acute gastric ulcer assay, which is induced by HCl/EtOH and nonsteroidal anti-inflammatory drugs (NSAIDs). Also, in the chronic ulcer assay, induced by acetic acid, the oral administration of ESC extract (250 mg/kg) reduced the ulcerated area, suggesting that it has a curative potential. The isolated compounds (30 mg/kg) exhibited gastroprotective activity in acute gastric ulcer assay, except cernumidine. The results indicated that the ESC extract was able to reduce the concentration of H+ ions in comparison with the control group. However, ESC extract did not modify the pH of the gastric juice acid and there was no significant increment in the amount of gastric adherent mucus in pretreated group. Further, it was evaluated the role of nitric oxide (NO) and sulfhydryl (SH) groups on the gastroprotective effect elicited by ESC extract. The results showed that gastroprotection induced by the ESC extract is correlated with the presence of endogenous NO and SH groups which were responsible for gastroprotective activity. In the anti-angiogenic activity assay evaluated in HUVEC cells, the FBuOH fraction (50 ?g/mL) and the cernumidine alkaloid (160 nM) inhibited the the formation of endothelial vessels by 62.75% and 77.73%, respectively. Different concentrations of the ESC extract and cernumidine alkaloid were further tested in primary culture of iv smooth muscle HPB for 48, 72 and 96 h. ESC extract (3 mg/mL) and the alkaloid (1 mg/mL; 3.3 x 10-6 M) treatment for 96 h inhibited the cell growth by 60% and 62%, respectively. In addition, it was assessed the potential effect of extract and its constituents to induce apoptosis by performing the annexin Cy5 assay by flow cytometry. Treatment with ESC extract and cernumidine alkaloid led to cell death by apoptosis. Only cernumidine at 1 mg/mL showed significant cells death by necrosis compared to control. Considering the spray dryer technique to dry the extract, the yield, bulk and tapped densities, particle size (D50) and the content of the cernumidine are influenced by some of the evaluated factors: temperature, flow and excipient percentage, linearly or quadratic form. To optimize the drying by spray dryer, it was used the desirability function. It was observed that the proximity of the predicted values of the yield and cernumidine content with the real values were found, showing the reliability of this mathematical method. Therefore, the obtained results corroborate the folk use and open new opportunities for the development of a phytotherapic from S. cernuum.
Suter, Andy. "New perspectives on saw palmetto (Serenoa repens) : a medico historical / analytical comparison of preparations derived from it and a clinical pilot trial in patients with benign prostatic hyperplasia and sexual dysfunctions". Thesis, University College London (University of London), 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.569065.
Pełny tekst źródłaNeves, Adriana Freitas. "Variações transcricionais dos genes AR, SRD5A2, KLK2, PCA3, KLK3 e PSMA e implicações no diagnóstico molecular do câncer de próstata". Universidade Federal de Uberlândia, 2007. https://repositorio.ufu.br/handle/123456789/15771.
Pełny tekst źródłaCHAPTER I - Prostate cancer is a common disease in the world and in some countries it is one of the main causes of male population mortality. Some molecular markers have been associated with prostate carcinogenesis. To observe changes in transcript levels of the AR, SRD5A2, KLK2, PSMA and PCA3 genes, the mRNA was analyzed in tissues with prostatic adenocarcinoma (PCa, N= 48) and benign prostatic hyperplasia (BPH, N= 25), performed through a differential multiplex RT-PCR assay. Significant differences were observed in the relative expression of these genes between cancerous and non-cancerous tissues. The optical density ratio of the cDNA amplicons between PCa and BPH for the AR gene was 1.6-fold higher for the prostatic adenocarcinoma. On the other hand, the SRD5A2 mRNA levels were associated with BPH and were 1.4-fold higher than that of PCa. For KLK2, PSMA and PCA3, the transcriptional levels were respectively, 1.9-, 1.9- and 5-fold higher in PCa than those in BPH tissues. Of the diagnostics tests carried through individually, the PCA3 gene was that presented higher sensitivity and accuracy, and the inclusion of the serum PSA improved the sensitivity (of 76 to 92%), positive preditive value (of 85 to 94%), negative preditive value (of 60 to 62%) and accuracy (of 74 to 78%). The results suggest that the higher AR, KLK2, PSMA, and PCA3 and/or reduced SRD5A2 genes expression in prostatic tissues may indicate the occurrence of prostate adenocarcinoma; however the PCA3 and serum PSA analysis together are highly promising as auxiliary method in the diagnosis of this cancer. CHAPTER II - Purpose: Prostate cancer (PCa) is the most commonly diagnosed malignancy in men, and it consists of multifactorial and multifocal events. Due to the complexity of the disease process, which includes genome alterations, local invasion, micrometastatic cell extravasations to circulation, invasion of secondary organ tissues, and resistance to hormonal blockage, many markers must be used to represent the multiple and variable events that lead to cancer development. The low specificity of the unique serum marker for prostate cancer diagnostics, PSA, has leaded us to investigate four potential markers in the peripheral blood of patients by detecting their mRNA levels and associating them to clinical parameters. Methods: The expression levels of the KLK2, KLK3, PCA3 and PSMA transcripts were determined by Nested RT-PCR. Patients with PCa (99) and with benign prostatic hyperplasia (BPH, 36), and healthy volunteers (104) were investigated. Results: Significant differences for the RNA relative levels have been found for the KLK2, PCA3 and PSMA transcripts between PCa and BPH patients or healthy volunteers. The KLK2 and PSMA levels also presented a positive association (P<0.05) with extra-prostatic disease (pT3). The combined positive RT-PCR Nested for the KLK2, PCA3, PSMA genes with serum PSA higher than 4ng/mL presented a 10-fold higher chance of cancer occurrence than healthy controls, with sensitivity, specificity and positive predictive value of 57%, 89% and 93%, respectively. Conclusions: The combined analysis of KLK2, PCA3 and PSMA transcripts may become a useful tool for the discrimination of PCa patients from those with benign disease or healthy individuals. Additionally, the KLK2 and PSMA transcripts may also be used as prognostic markers for the presence of extra-capsular disease and assisting in the prediction of the post-operative outcome. CHAPTER III - Purpose: Transcripts of PCA3/DD3 gene are at the moment the most specific molecule found in prostate cancer specimens. This mRNA can be detected in important sample targets for clinical analyses, such as prostatic tissues, urine after prostatic massage, and the peripheral blood. Methods: The present study evaluated the PCA3 gene expression in prostatic tissues and in peripheral blood of BPH and PCa patients, by RT-PCR assays, and based on its detection together with other clinical parameters, we proposed a model for molecular monitoring in order to improve diagnosis as an auxiliary technology. Results: The concomitant use of PCA3 transcript detection in the peripheral blood and in prostate tissues has improved diagnosis, with sensitivity and an accuracy of 77%. For the molecular staging, patients have been classified as: localized disease (PBL-; negative PCA3) and circulating tumors cells disease (PBL+; positive PCA3). The higher frequencies of PBL- had been observed in T1-T2 stages (75%); on the other hand, the higher PCA3 positivity was observed for the T3-T4 staging (43%), while the T1-T2 stages presented 25% positivity. A correlation was found between the molecular staging and serum PSA < 10ng/mL before surgery, and approximately 60% of patients with T3-T4 stages that presented biochemical failure after radical prostatectomy presented a positive PCA3 result (P= 0.05), with an odds ratio of 16-fold higher for the possibility of disease recurrence in relation to the T1-T2 patients, and an accuracy of 82%. Conclusion: These data demonstrated the importance of the PCA3 gene as an auxiliary method in prostate cancer diagnosis, by distinguishing PCa from BPH patients, and also demonstrated its prognostic value in recurrent disease for post-operative patients. CHAPTER IV - Approximately 98% of all the products transcribed in the human genome correspond to non coding RNAs (ncRNA). Many ncRNA functions are attributed to this structural particularity given mainly for the secondary structures formed from its linear sequence of bases. Among the ncRNA types are tRNA, rRNA, small nuclear RNA, small nucleolar RNA, small interference RNA (siRNA), microRNA (miRNA) and catalytic RNAs (ribozymes). The bioinformatics has supplied useful tools in the prediction of optimal or suboptimal secondary structures allowing the design of interference RNA as miRNAs or siRNAs. In human, miRNAs have been associated with the development of diverse complex diseases as cancer. The PCA3 (DD3) gene was molecularly characterized as cancer and prostate specific, and its transcripts are non-coding, once no peptide products have been found. Due to its structural characteristics, the PCA3 gene belongs thus to the increasing family of ncRNA. In the present work, four new variant molecules of the PCA3 gene have been sequence characterized and their frequencies demonstrated in prostate cancer and in benign prostatic hyperplasia patients, as well as in healthy individuals. We have also investigated and predicted the putative secondary structures formed in order to elucidate its role in prostate cancer biology. No association has been found between the frequency of these molecules and prostate pathologies (PCa or BPH). On the other hand, PCA3 variants were found in 10% (12/115) of cases in the general population. Similar analyses of the possible polypeptides of these molecules demonstrated that it remains as a non-coding RNA, and introns presents in the first, second and fourth variants suggesting a possible role as a miRNA with intracellular activity to these molecules to the PCA3 gene. In prostatic tissues, 100% of the prostate cancer cases presented the RNA molecule with an exon 2 splicing. However, further investigation must be carried out to demonstrate the true role of these splicing variants in prostate tumors and in other pathologies, once these molecules have been preferentially found in the peripheral blood.
CAPÍTULO I - O câncer de próstata é uma doença comum no mundo e já assumiu em alguns países uma das principais causas de mortalidade da população masculina. Vários marcadores moleculares têm sido associados à gênese do câncer de próstata. A fim de demonstrar a expressão diferencial dos níveis transcricionais dos genes AR, SRD5A2, KLK2, PSMA e PCA3 em doenças prostáticas, o RNAm foi analisado em tecidos com adenocarcinoma prostático (CaP, N= 48) e hiperplasia prostática benigna (HPB, N= 25) por meio da técnica RT-PCR multiplex semi-quantitativa. Foram observadas diferenças significativas na expressão relativa desses genes entre os tecidos cancerosos e nãocancerosos. A taxa de densidade ótica entre os amplicons para cDNA provenientes do gene AR foi 1.6 vezes maior no adenocarcinoma prostático. Por outro lado, os níveis de RNAm do gene SRD5A2 foi associado com a HPB e foi 1.4 vezes maior do que no CaP. Para os genes KLK2, PSMA e PCA3, os níveis transcricionais foram respectivamente, 1.9, 1.9 e 5 vezes maior no câncer comparado a tecidos benignos. Dos testes diagnósticos realizados, o gene PCA3 individualmente foi o que apresentou as melhores sensibilidade e acurácia, sendo que a inclusão das medidas de PSA sérico melhorou a sensibilidade (de 76 para 92%), o valor preditivo positivo (de 85 para 94%), o valor preditivo negativo (de 60 para 62%) e a acurácia (de 74 para 78%). Os dados sugerem que a maior expressão dos genes AR, KLK2, PSMA e PCA3 ou expressão reduzida do gene SRD5A2 em tecidos prostáticos podem indicar a ocorrência do adenocarcinoma da próstata, sendo que as análises do gene PCA3 juntamente aos do PSA sérico são altamente promissores como método auxiliar no diagnóstico desse tipo de câncer. CAPÍTULO II - O câncer de próstata (CaP) e o mais comumente diagnosticado na população masculina e consiste de eventos multifatoriais e multifocais. Devido a complexidade da doença, a qual inclui alterações genômicas, invasão local, liberação de células micrometastáticas para a circulação, invasão secundaria de tecidos de outros órgãos, e resistência ao bloqueio hormonal, muitos marcadores podem ser usados para representar os eventos múltiplos e variáveis que levam ao desenvolvimento do câncer. A baixa especificidade do único marcador para diagnostico do câncer de próstata, PSA, tem nos levado a investigar quatro potenciais marcadores no sangue periférico de pacientes pela detecção de seus níveis de RNAm e associá-los a parâmetros clínicos. Os níveis de expressão dos transcritos do KLK2, KLK3, PCA3 e PSMA foram avaliados pela RT-PCR Nested, em pacientes com CaP (99), com hiperplasia prostática benigna (HPB, 36) e voluntários saudáveis (104). Diferenças significativas foram encontradas para a expressão dos genes KLK2, PSMA e PCA3 entre os pacientes com CaP e os pacientes com HPB ou voluntários saudáveis. Os níveis do KLK2 e PSMA também apresentaram associação positiva (P<0.05) com doença extra-prostática (pT3). A RT-PCR Nested positiva combinada para os genes KLK2, PCA3 e PSMA com PSA sérico maior que 4ng/mL apresentou uma chance 10 vezes maior de ocorrência do câncer comparado aos controles saudáveis, com sensibilidade, especificidade e acurácia de 57%, 89% e 93%, respectivamente. A análise combinada dos genes KLK2, PCA3 e PSMA pode ser uma ferramenta útil na distinção de pacientes com CaP daqueles com doença benigna ou de indivíduos saudáveis. Ainda, a analise dos transcritos KLK2 e PSMA podem ser usados como marcadores prognósticos para a presença de doença extra-capsular e auxiliando na predição de recidiva da doença no pós-operatório. CAPÍTULO III - Os transcritos do gene PCA3/DD3 são até o momento as moléculas mais específicas encontradas em espécimes de câncer de próstata. Esses RNAm podem ser detectados em importantes alvos para a análise clínica como tecidos prostáticos, na urina após massagem prostática e em sangue periférico. O presente estudo avaliou a expressão do gene PCA3 em tecidos prostáticos e em sangue periférico de pacientes com HPB e CaP, por técnicas de RT-PCR, e baseado na sua detecção juntamente com os parâmetros clínicos, foi proposto um modelo de estadiamento molecular como técnica assessória para melhor o diagnóstico da doença. O uso concomitante da detecção dos transcritos do gene PCA3 no sangue periférico e no tecido prostático melhorou o diagnóstico, com sensibilidade e acurácia de 77%. Para o estadiamento molecular, os pacientes foram classificados como contendo a doença localizada (PBL-) e em doença com células tumorais circulantes (PBL +). Maiores freqüências de tumor localizado pelo estadiamento molecular foram observadas nos estadios T1-T2 (75%), enquanto que 25 e 43% dos cânceres T1-T2 e T3-T4, respectivamente, apresentaram PCA3 positivo (células circulantes). Uma correlação foi encontrada para o estadiamento molecular para doença localizada e PSA sérico pré-cirúrgico < 10ng/mL, e aproximadamente 60% dos pacientes TNM T3-T4 que apresentaram falha bioquímica após a cirurgia radical apresentaram RTPCR positiva do PCA3 (P= 0.05), com um Odds Ratio 16 vezes maior para a possibilidade de recorrência da doença em relação aos pacientes T1-T2 e uma acurácia de 82%. Esses dados demonstram a importância da detecção do gene PCA3 como método no diagnóstico do câncer de próstata, por distinguir pacientes com CaP daqueles com HPB, e também demonstrando seu valor prognóstico na doença recorrente no pósoperatório dos pacientes. CAPÍTULO IV - Aproximadamente 98% de todos os produtos transcritos do genoma humano correspondem a RNAs não codificantes (RNAnc). Muitas funções dos RNAnc são atribuídas a suas particularidades estruturais dadas principalmente pelas estruturas secundárias formadas a partir da sua sequência linear de bases. Dentre os tipos de RNAnc estão os RNAt, RNAr, small nuclear RNA, small nucleolar RNA, small interference RNA (siRNA), microRNA (miRNA) e RNAs catalíticos (ribozimas). A bioinformática tem fornecido ferramentas úteis na predição de estruturas secundárias ótimas ou subótimas permitindo o design de RNAs de interferência como os miRNAs ou siRNAs. Em humanos, os miRNAs tem sido associados ao desenvolvimento de diversas doenças complexas como o câncer. O gene PCA3 (DD3) foi molecularmente caracterizado como câncer- e próstata- específico e os seus RNAs são os responsáveis por essa característica, isso porque nenhum produto protéico tem sido encontrado para esse gene. Devido às suas características estruturais, o gene PCA3, pertence assim à crescente família de RNAnc. No presente trabalho foi analisado as freqüências de quatro moléculas variantes do gene PCA3, além das anteriormente reportadas, como também foram preditas as suas estruturas secundárias na tentativa de elucidar o seu papel na biologia do câncer de próstata. Nenhuma associação foi encontrada entre a freqüência dessas moléculas e as patologias da próstata como hiperplasia benigna ou câncer, sendo que na população geral analisada essas variantes foram encontradas em apenas 10% (12/115) dos casos. As análises de homologia de possíveis polipeptídeos para essas moléculas demonstram que permanece o papel de RNA não-codificante para o gene PCA3. Ainda, a presença de introns nas variantes 1, 2 e 4 podem sugerir um papel intracelular de miRNA para essas moléculas do gene PCA3. Nos tecidos prostáticos, 100% dos casos de câncer foi representando pela molécula com splicing do exon 2. Contudo, para as variantes de splicing, novas pesquisas deverão ser realizadas incluindo outras patologias além das doenças prostáticas e outros tipos tumorais para verificar o real impacto dessas moléculas, uma vez que foram encontradas preferencialmente no sangue periférico.
Doutor em Genética e Bioquímica
Marklund-Bau, Helén. "Sleep and quality of life in men with lower urinary tract symptoms : and their partners". Doctoral thesis, Linköpings universitet, Hälsouniversitetet, 2009. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-15946.
Pełny tekst źródłaManseck, Andreas, Christian Pilarsky, Stefan E. Froschermaier, Mario Menschikowski i Manfred P. Wirth. "Diagnostic Significance of Prostate-Specific Antigen Velocity at Intermediate PSA Serum Levels in Relation to the Standard Deviation of Different Test Systems". Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133947.
Pełny tekst źródłaDieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
Tacino, Rafael Bozzo. "Efeitos do uso da finasterida sobre o volume prostático e dosagem sérica do PSA em pacientes jovens". Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/17/17137/tde-02022016-093721/.
Pełny tekst źródłaThe indication of biopsy for early diagnosis of prostate cancer is based on serum PSA levels and digital rectal examination findings. PSA is a kalecreine and its regulatory genes are modulating by androgens. Drugs affecting the androgens metabolism can affect the production of PSA. Finasteride is a synthetic drug, which inhibits the conversion of testosterone to DHT by the enzyme 5 AR. There are two subtypes of 5AR enzymes, Type 1 that predominates in non-prostatic tissues such as liver and skin, and Type 2, which predominates in the prostate and scalp but is also expressed in other tissues. The use of Finasteride 5mg / day for the treatment of BPH is well known. After six months we observe a decrease in prostate volume by 20 to 30% and also a decrease in total serum PSA concentration of approximately 50%. The use of Finasteride at 1mg / day for the treatment of MAA has been approved by the FDA in 1997. In 2007 a study evaluated the change in total serum PSA concentration in men over 40 years taking Finasteride 1 mg / day to treat MAA. The results showed a reduction in PSA values similar to that observed in patients treated of BPH. There are no prospective studies including younger patients. The aim of our study was to assess the changes in total serum PSA concentration, total serum testosterone concentration and prostate volume in patients younger than 40 years of age in use of Finasteride 1mg / day for MAA. We prospectively selected 52 patients with MAA and indication for treatment with Finasteride who met the inclusion criteria. Serum levels of total PSA and total testosterone and prostate volume, measured by transabdominal ultrasound, were obtained at baseline (T0) and one year after started the drug (T2). In the interval, 6 months after started drug, only serum total PSA concentration was measured (T1). The median value at baseline (T0), for total PSA, total testosterone and prostate volume was 0.398 ng / ml (0.14 to 0.78); 735.77 ng / dl (548-927) and 21.35 ml (15-31ml) respectively. A reduction of 9.21% on total PSA concentration was detected 6 months after started the drug (p = 0.001). After 12 months we observed a 10.51% decrease in total serum PSA concentration, when compared with the baseline value, (p <0.001). A reduction in the median value of prostate volume from 21.37 ml to 20.03 ml (p < 0.001) was also detected at the same period. There were no detectable changes in testosterone levels. They reported a decrease of 40% and 50% in total PSA concentration for groups between 40-49 and 50-59 of age respectively. In our study we observed lower reductions. Our finding may be explained by the fact that the epithelial component of the prostate gland has not yet started the hyperplasia process, so the conversion of testosterone into DHT by blocking 5AR by Finasteride would cause less impact. The fact that the values of plasma testosterone not have changed is not surprising since Finasteride is not considered an anti androgenic drug, it means that the synthesis of the testosterone is not affected by its use. Our study highlights important questions about how the adjustment of PSA values should be done in patients who began taking Finasteride 1mg / day before 40 years of age and present for prostate evaluation. Another point of interest is whether the hyperplasia of the epithelial component, observed during the aging process, could be inhibited by the use of Finasteride. This hypothesis can be corroborate by the fact that individuals with congenital deficiency of 5AR do not present alopecia or develop BPH. In conclusion the use of Finasteride 1mg /day reduces the total serum PSA value by 10,51% after one year. Prostate volume is also reduced by 6,3% in the same period.